• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Lichen International Limited

    11/7/25 4:31:12 PM ET
    $LICN
    Professional Services
    Consumer Discretionary
    Get the next $LICN alert in real time by email
    S-8 1 licns8103025.htm FORM S-8

    As filed with the Securities and Exchange Commission on November 7, 2025

    Registration No. 333-     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM S-8

     

     

     

    REGISTRATION STATEMENT

    UNDER
    THE SECURITIES ACT OF 1933

     

    Lichen International Limited

    (Exact Name of Registrant as Specified in its Memorandum and Articles of Association)

     

    Cayman Islands   N/A
    (State or Other Jurisdiction of
    Incorporation or Organization)
      (I.R.S. Employer
    Identification No.)

     

    15th Floor, Xingang Square, Hubin North Road,
    Siming District, Xiamen City,
    Fujian Province, China,
    +86-592-5586999
      361013
    (Address of Principal Executive Offices)   (Zip Code)

     

    2025 Equity Incentive Plan

    (Full Title of the Plan)

     

    Cogency Global Inc.

    122 East 42nd Street, 18th Floor

    New York, New York 10168

    (Name and Address of Agent for Service)

     

    800-221-0102

    (Telephone Number, Including Area Code, of Agent for Service)

     

    Copy To:

     

    William S. Rosenstadt, Esq.

    Mengyi “Jason” Ye, Esq.
    Yarona L. Yieh, Esq.
    Ortoli Rosenstadt LLP
    366 Madison Avenue, 3rd Floor
    New York, NY 10017
    Tel: +1-212-588-0022

    Fax: +1-212-826-9307

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☐
      Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    EXPLANATORY NOTE

     

    This registration statement (this “Registration Statement”) is filed by Lichen International Limited, an exempted company incorporated under the laws of the Cayman Islands (the “Registrant”) to register securities issuable pursuant to the Lichen International Limited 2025 Equity Incentive Plan (as amended and restated, the “2025 Equity Incentive Plan”). The securities registered hereby consist of 2,500,000 series A ordinary shares, US$0.008 par value per share of the Registrant (“Class A Ordinary Shares”), which represent the number of Class A Ordinary Shares that were authorized under the 2025 Equity Incentive Plan. Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also covers an indeterminate number of additional shares which may be offered and issued to prevent dilution from share splits, share dividends or similar transactions as provided in the 2025 Equity Incentive Plan. Any Class A Ordinary Shares covered by an award granted under the 2025 Equity Incentive Plan (or portion of an award) that terminates, expires, lapses or repurchased for any reason will be deemed not to have been issued for purposes of determining the maximum aggregate number of Class A Ordinary Shares that may be issued under the 2025 Equity Incentive Plan.

     

     

    PART I

     

    INFORMATION REQUIRED IN THE 10(A) PROSPECTUS

     

    Item 1. Plan Information*

     

    Item 2. Registrant Information and Employee Plan Annual Information*

     

    *The documents containing the information specified in “Item 1. Plan Information” and “Item 2. Registrant Information and Employee Plan Annual Information” of Form S-8 will be sent or given to participants of the 2025 Equity Incentive Plan, as specified by Rule 428(b)(1) under the Securities Act. Such documents are not required to be, and are not, filed with the Securities and Exchange Commission (the “Commission”) either as part of this Registration Statement or as a prospectus or prospectus supplement pursuant to Rule 424 under the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents, and all documents we subsequently file pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and shall be deemed to be a part hereof from the date of the filing of such documents:

     

    (1)our Annual Report on Form 20-F for the fiscal year ended December 31, 2024, filed with the Commission on April 29, 2025;

     

    (2)our Reports on Form 6-K, filed with the Commission on September 10, 2025, September 19, 2025, September 19, 2025, and November 7, 2025;

     

    (3)The description of our ordinary shares incorporated by reference in our registration statement on Form 8-A, as amended (File No. 001-41493) filed with the Commission on September 7, 2022, including any amendment and report subsequently filed for the purpose of updating that description; and

     

    (4)all reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the report referred to in (1) above.

     

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold, or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or deemed to be incorporated by reference herein modifies or supersedes such statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    II-1

     

    Item 6. Indemnification of Directors and Officers.

     

    Cayman law does not prohibit or restrict a company from indemnifying its directors and officers against personal liability for any loss they may incur arising out of the company’s business. A company’s articles may provide for the indemnification of a director or an officer for breach of duty, save in circumstances where there has been wilful neglect, wilful default, fraud or dishonesty in the carrying out of fiduciary duties.

     

    Our Amended and Restated Memorandum and Articles of Association provide that the Company shall indemnify each Director and officer of the Company and any trustee acting in relation to any of the affairs of the Company and their heirs, executors, administrators and personal representatives respectively, out of the assets of the Company from and against all actions, proceedings, costs, charges, losses, damages and expenses which they or any of them shall or may incur or sustain by reason of any act done or omitted in or about the execution of their duty in their respective offices or trusts, except such (if any) as they shall incur or sustain by or through their own wilful neglect or default respectively and no such Director, officer or trustee shall be answerable for the acts, receipts, neglects or defaults of any other Director, officer or trustee or for joining in any receipt for the sake of conformity or for the solvency or honesty of any banker or other persons with whom any monies or effects belonging to the Company may be lodged or deposited for safe custody or for any insufficiency of any security upon which any monies of the Company may be invested or for any other loss or damage due to any such cause as aforesaid or which may happen in or about the execution of his office or trust unless the same shall happen through the wilful neglect or default of such Director, officer or trustee.

     

    In addition, we have entered into indemnification agreements with our prior directors and executive officers that provide such persons with additional indemnification beyond that provided in our Amended and Restated Memorandum and Articles of Association.

     

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling us under the foregoing provisions, we have been informed that in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    Reference is hereby made to the Exhibit Index, which is incorporated herein by reference.

     

    II-2

     

    Item 9. Undertakings.

     

    A. The undersigned Registrant hereby undertakes:

     

    (1)To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (a)To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (b)To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement; and

     

    (c)To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

     

    provided, however, that paragraphs (1)(a) and (1)(b) above do not apply if the information required to be included in a post- effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

     

    (2)That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3)To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    B. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    C. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that, in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    II-3

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
    4.1   The Amended and Restated Memorandum and Articles of Association (incorporated by reference to Exhibit 3.1 to our report on Form 6-K filed with the SEC on February 12, 2025)
         
    5.1   Opinion of Appleby, the Cayman Islands counsel of the Company, regarding the validity of the securities being registered (filed herewith)
         
    10.1   2025 Equity Incentive Plan of Lichen International Limited (incorporated by reference to Exhibit 99.1 to the report on Form 6-K filed with the SEC on November 7, 2025)
         
    23.1   Consent of Appleby (included in Exhibit 5.1)
         
    23.2   Consent of Enrome LLP (filed herewith)
         
    23.3   Consent of TPS Thayer, LLC (filed herewith)
         
    107   Filing Fee Table (filed herewith)

     

    II-4

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in China, on November 7, 2025.

     

    Lichen International Limited  
         
    By: /s/ Ya Li  
    Name: Ya Li  
    Title: Chief Executive Officer  

     

    Signature   Title   Date
             
    /s/ Ya Li   Chief Executive Officer and Chairman of the Board   November 7, 2025
    Ya Li   (Principal Executive Officer and Director)    
             
    /s/ Zhixiang Fang   Chief Financial Officer   November 7, 2025
    Zhixiang Fang   (Principal Financial and Accounting Officer)    
             
    /s/ Yi Deng   Director   November 7, 2025
    Yi Deng        
             
    /s/ Zhihuang Deng   Director   November 7, 2025
    Zhihuang Deng        
             
    /s/ Robert Bodenstein   Director   November 7, 2025
    Robert Bodenstein        
             
    /s/ Jingyu Lian   Director   November 7, 2025
    Jingyu Lian        

     

    II-5

     

    SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

     

    Pursuant to the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of Lichen International Limited, has signed this registration statement or amendment thereto in New York, NY on November 7, 2025.

     

    Authorized U.S. Representative  
    Cogency Global Inc.  
         
    By: /s/ Colleen A. De Vries  
      Name: Colleen A. De Vries  
      Title: Senior Vice President  

     

    II-6

    Get the next $LICN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LICN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LICN
    SEC Filings

    View All

    SEC Form 6-K filed by Lichen International Limited

    6-K - Lichen International Ltd (0001876766) (Filer)

    1/7/26 5:00:32 PM ET
    $LICN
    Professional Services
    Consumer Discretionary

    SEC Form 6-K filed by Lichen International Limited

    6-K - Lichen International Ltd (0001876766) (Filer)

    12/11/25 4:30:15 PM ET
    $LICN
    Professional Services
    Consumer Discretionary

    SEC Form EFFECT filed by Lichen International Limited

    EFFECT - Lichen International Ltd (0001876766) (Filer)

    12/11/25 12:15:18 AM ET
    $LICN
    Professional Services
    Consumer Discretionary

    $LICN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lichen China Limited Announces Effective Date of Reverse Stock Split and Name Change

    XIAMEN, China, Feb. 27, 2025 /PRNewswire/ -- Lichen China Limited (Nasdaq: LICN) ("Lichen China" or the "Company"), a dedicated financial and taxation service provider in China today announced the date of effectiveness and the ratio of a forthcoming reverse stock split (the "Reverse Split") of the Company's ordinary shares (the "Ordinary Shares"). On February 12, 2025, the Company announced, on a Current Report on Form 6-K, the voting results from the annual meeting of shareholders (the "Meeting") held on February 10, 2025. At the Meeting, shareholders voted upon and approved Proposal 2 to effect a Reverse Split with a ratio of not less than one-for-twenty and not more than one-for-two-hundr

    2/27/25 8:30:00 AM ET
    $LICN
    Professional Services
    Consumer Discretionary

    Lichen China Limited Announces Receipt of Nasdaq Delisting Notice Subject to Hearing Request

    XIAMEN, China, Feb. 18, 2025 /PRNewswire/ -- Lichen China Limited (Nasdaq: LICN) ("Lichen China" or the "Company"), a dedicated financial and taxation service provider in China today announced that it has received a letter from The Nasdaq Stock Market LLC ("Nasdaq"), notifying that the Company is not in compliance with Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the "Low Priced Stocks Rule"), as the Company's securities had a closing bid price of $0.10 or less for eleven consecutive trading days from January 28, 2025 through February 11, 2025. The letter indicated that, as a result, the Nasdaq staff has determined to delist the Company's ordinary shares from The Nasdaq Capital Market (the "Delis

    2/18/25 8:00:00 AM ET
    $LICN
    Professional Services
    Consumer Discretionary

    Lichen China Limited Acquires Remaining Equity in Bondly Enterprises to Strengthen AI Development and Business Integration

    XIAMEN, China, Feb. 10, 2025 /PRNewswire/ -- Lichen China Limited (the "Company" or "Lichen China") (NASDAQ:LICN), a leading financial and taxation service provider in China, today announced the completion of its acquisition of the remaining 40% equity interest in Bondly Enterprises Limited ("Bondly"), a prominent domestic consulting firm specializing in business process management and informationization. This acquisition follows Lichen China's initial purchase of 60% equity in Bondly in 2024, and marks a significant step in Lichen China's strategy to fully integrate Bondly's advanced technologies and AI capabilities into its operations. The acquisition, valued at US$5,330,000, underscores

    2/10/25 8:00:00 AM ET
    $LICN
    Professional Services
    Consumer Discretionary

    $LICN
    Financials

    Live finance-specific insights

    View All

    Lichen China Limited Acquires Remaining Equity in Bondly Enterprises to Strengthen AI Development and Business Integration

    XIAMEN, China, Feb. 10, 2025 /PRNewswire/ -- Lichen China Limited (the "Company" or "Lichen China") (NASDAQ:LICN), a leading financial and taxation service provider in China, today announced the completion of its acquisition of the remaining 40% equity interest in Bondly Enterprises Limited ("Bondly"), a prominent domestic consulting firm specializing in business process management and informationization. This acquisition follows Lichen China's initial purchase of 60% equity in Bondly in 2024, and marks a significant step in Lichen China's strategy to fully integrate Bondly's advanced technologies and AI capabilities into its operations. The acquisition, valued at US$5,330,000, underscores

    2/10/25 8:00:00 AM ET
    $LICN
    Professional Services
    Consumer Discretionary

    Lichen China Limited Announced Financial Results for Fiscal Year 2023

    XIAMEN, China, April 5, 2024 /PRNewswire/ -- Lichen China Limited (the "Company" or "Lichen China")(NASDAQ:LICN), a dedicated financial and taxation service provider in China, today announced its financial results for the fiscal year ended December 31, 2023. FY 2023 Financial Highlights: Revenue increased approximately $5.95 million or 17.61% to approximately $39.76 million for the year ended December 31, 2023, as compared with approximately $33.81 million for the fiscal year ended December 31, 2022. The increase was primarily due to continuous expansion of the branding and business that brought new clients and orders.Gross profit was approximately $24.32 million for the fiscal year ended D

    4/5/24 8:00:00 AM ET
    $LICN
    Professional Services
    Consumer Discretionary

    $LICN
    Leadership Updates

    Live Leadership Updates

    View All

    Lichen China Limited Announces Appointment of Robert Bodenstein to Board of Directors

    XIAMEN, China, Feb. 27, 2024 /PRNewswire/ -- Lichen China Limited (the "Company" or "Lichen China")(NASDAQ:LICN), a dedicated financial and taxation service provider in China, announced the appointment of Mr. Robert Bodenstein to its board of directors, effective February 26, 2024. Mr. Bodenstein will serve as an independent director as well as a member of the Nominating, Compensation and Audit Committees. Mr. Bodenstein, with over 40 years of experience in the management consulting industry, serves as the Chair of the International Council of Management Consulting Institutes (ICMCI), a global alliance of management consulting institutes, recognized by the United Nations Economic and Social

    2/27/24 8:00:00 AM ET
    $LICN
    Professional Services
    Consumer Discretionary